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Abstract
 Purpose—MYC is a critical driver oncogene in many cancers, and its deregulation in the 
forms of translocation and overexpression has been implicated in lymphomagenesis and 
progression of diffuse large B-cell lymphoma (DLBCL). The MYC mutational profile and its roles 
in DLBCL are unknown. This study aims to determine the spectrum of MYC mutations in a large 
group of DLBCL patients, and to evaluate the clinical significance of MYC mutations in DLBCL 
patients treated with R-CHOP immunochemotherapy.
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 Experimental Design—We identified MYC mutations in 750 DLBCL patients using Sanger 
sequencing and evaluated the prognostic significance in 602 R-CHOP-treated patients.
 Results—The frequency of MYC mutations was 33.3% at the DNA level (mutations in either 
the coding sequence or the untranslated regions), and 16.1% at the protein level (nonsynonymous 
mutations). Most of the nonsynonymous mutations correlated with better survival outcomes; in 
contrast, T58 and F138 mutations (which were associated with MYC rearrangements), as well as 
several mutations occurred at the 3´ untranslated region, correlated with significantly worse 
survival outcomes. However, these mutations occurred infrequently (only in approximately 2% of 
DLBCL). A germline single nucleotide polymorphism encoding the Myc-N11S variant (observed 
in 6.5% of the study cohort) was associated with significantly better patient survival, and resulted 
in reduced tumorigenecity in mouse xenografts.
 Conclusions—Various types of MYC gene mutations are present in DLBCL and show 
different impact on Myc function and clinical outcomes. Unlike MYC gene translocations and 
overexpression, most MYC gene mutations may not have a role in driving lymphomagenesis.
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 INTRODUCTION
MYC is a proto-oncogene encoding the Myc protein, a transcription factor critical for cell 
proliferation, metabolism, differentiation, apoptosis, microenvironment remodeling and 
immune responses. MYC-IGH chromosomal rearrangement, resulted from aberrant class-
switch recombination during germinal center (GC) reaction and leading to Myc 
overexpression, underlies the pathogenesis of Burkitt lymphoma, and the poorer prognosis 
of ∼10% of diffuse large B-cell lymphoma (DLBCL) associated with MYC translocation 
(1). Paradoxically, Myc overexpression is also a potent inducer of apoptosis through the 
modulation of both p53-dependent and p53-independent pathways, including the activation 
of TP53, ARF, CD95/FAS, and BAX, and the inhibition of BCL2, BCLX, and CFLAR/FLIP 
(2). Therefore, in tumors deregulation of MYC is often concomitant with other 
abnormalities (e.g., Bcl-2 overexpression) that cooperate with Myc during tumor onset, 
progression and chemoresistance (3–5).
In addition to MYC rearrangement, MYC mutation is another form of genetic abnormality 
found in Burkitt lymphoma. Multiple nonsynonymous mutations in the coding sequence 
(CDS) of the MYC gene have been found in approximately 40–70% of Burkitt lymphoma 
leading to a mutated Myc protein with amino acid changes (6–9). These Myc mutations 
cluster in the Myc transactivation domain with hotspots in the Myc box I (MBI) motif (44–
63aa, Figure 1A), and have been proposed to have a role in lymphomagenesis by enhancing 
the oncogenicity of Myc (9–12). Functional studies indicated that Myc T58 mutants had 
increased transforming ability, increased Myc stability, and decreased proapoptotic ability, 
owing to alterations in posttranslational modifications of Myc. In contrast, S62 mutations, 
which are also frequent in the MBI motif and are associated with increased Myc expression, 
lead to decreased transforming ability without affecting apoptosis (10,13–17); the F138C 
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mutation in the Myc box II (MBII) motif (128–143aa) decreases both transformation and 
apoptosis (18); and deletion of residues 188–199 in the Myc box III (MBIII) motif correlates 
with increased response to apoptosis and decreased tumorigenic ability in vivo (19). 
Moreover, somatic mutations exist in noncoding MYC exon I (5´ untranslated region [UTR]) 
(20,21) and within intron 1 near the exon 1 boundary (22), which may represent another 
pathogenic mechanism by deregulating MYC expression (20). For example, in Burkitt 
lymphoma, mutations at the 3´ border of MYC exon I remove a block to transcriptional 
elongation (23), and in multiple myeloma, mutations in the MYC internal ribosome entry 
segment lead to enhanced translation initiation (24).
DLBCL also harbors MYC mutations, as shown by several studies (25–27). Sanger 
sequencing found DLBCL-specific MYC mutations (absent in GC-derived follicular 
lymphoma, pre-GC mantle-cell lymphoma, post-GC multiple myeloma and VH-mutated 
chronic lymphocytic leukemia as well as normal tissues) in the 5´UTR and CDS regions of 
the MYC gene harbored by 12 (32%) of 37 DLBCL patients; these mutations were proposed 
to originate from aberrant somatic hypermutation processes during DLBCL 
lymphomagenesis (25). Through next-generation sequencing, six of 111 DLBCL biopsies 
were found to have MYC mutations (26). However, the clinical relevance of MYC mutations 
in DLBCL has not been addressed.
To fill this knowledge gap, this study aims to profile the spectrum and frequency of MYC 
mutations in a large cohort of DLBCL patients, to study the functional consequences and to 
evaluate the prognostic significance of these MYC mutations.
 PATIENTS AND METHODS
 Patients
The study cohort consists of 750 patients with de novo DLBCL between 2000 and 2010 
according to the World Health Organization classification criteria as a part of the 
International DLBCL R-CHOP Consortium Program. Patients with transformed DLBCL, 
primary mediastinal, cutaneous, or central nervous system large B-cell lymphomas, or 
human immunodeficiency virus infection were excluded. Cell-of-origin classification by 
either gene expression profiling or immunohistochemical algorithms have been described 
previously (1,28). Survival analysis was performed for 602 patients treated with standard 
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (i.e., R-CHOP) 
chemotherapy whose follow-up data were available, randomly divided into a training set (n 
= 368) and a validation set (n = 234). At last follow-up, 208 of the 602 patients had died. 
The rest (394) patients were censored and had a median follow-up time of 54 months (range, 
3–187 months). This study was conducted in accordance with the Declaration of Helsinki 
and was approved either as minimal to no risk or as exempt from review by the Institutional 
Review Boards of all participating centers.
The clinicopathologic features of the patients with or without mutations at the time of 
presentation were compared using the Fisher’s exact test. Overall survival (OS) was 
calculated from the date of diagnosis to the date of death from any cause or last follow-up. 
Progression-free survival (PFS) was calculated from the date of diagnosis to the date of 
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disease progression, disease relapse, or death from any cause. Patients who were alive or had 
no disease progression were censored at the last follow-up. Survival analysis was performed 
using the Kaplan–Meier method with GraphPad Prism 6, and survival was compared 
between groups using the log-rank test. Multivariate survival analysis was performed using 
the Cox proportional hazards regression model with SPSS statistics software (version 19.0; 
IBM Corporation). All differences with P ≤ 0.05 were considered statistically significant 
(4,28–30).
 Gene Expression Profiling
For patients in the training set, total RNAs extracted from formalin-fixed, paraffin-embedded 
tissues were subjected to gene expression profiling (GEP) using the Affymetrix GeneChip 
Human Genome U133 Plus 2.0 as previously described (28). Totally 350 patients in the 
training sets have GEP achieved and the CEL files have been deposited in the National 
Center for Biotechnology Information Gene Expression Omnibus repository (GSE31312). 
Normalized microarray data underwent univariate analysis using a t-test to identify genes 
that were differentially expressed between various groups. The P values obtained by 
multiple t-tests were corrected for false discovery rates using the beta-uniform mixture 
method.
The mRNA expression levels of selected genes of interest were also compared between 
DLBCL groups by unpaired t-tests using GraphPad Software.
 Detection of MYC Mutations and Rearrangements, Assessment of Myc Expression, and 
Functional Studies of Myc Mutants in vitro and in vivo
Details of Sanger sequencing for MYC gene (in all patients), functional studies of Myc 
mutants in vitro and in vivo , fluorescence in situ hybridization for MYC rearrangement 
detection (successful in 455 patients), and Myc expression evaluation by 
immunohistochemistry (successful in 556 patients) performed on tissue microarrays using 
formalin-fixed, paraffin-embedded samples are in the supplementary documents or have 
been described previously (1,4,29,31).
 RESULTS
 MYC Gene Resequencing Results Overview
The MYC gene variants found in the 750 patients were predominantly single-nucleotide 
substitutions of the canonical MYC sequence. The single nucleotide variations (SNVs) from 
the MYC reference sequence (NG_007161.1) (wild-type [WT] MYC) were herein referred 
as either germline single nucleotide polymorphisms (SNPs, variations in the dbSNP database 
[Build 132]), or somatic mutations (MUT, the rest of SNVs). Fourteen SNPs were found in 
the MYC CDS. Of these, two SNPs were most prevalent: rs4645959 (32A>G) which results 
in Myc-11S protein, and rs2070582 (693G>A) which is synonymous (Figure 1B). After 
exclusion of SNPs, MYC gene mutations were found in 250 DLBCL patients (33.3% of the 
DLBCL cohort), mainly in the 5´UTR and CDS regions (Supplementary Table S1); 
mutations in the 3´UTR were much less frequent. Mutations at the splicing sites were rare (n 
= 2). Most (71.4%) of the mutations were heterozygous.
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Compared with the other nine genes we sequenced, MYC showed an elevated mutation rate 
in the 5´UTR although the mutation rate was significantly lower than that of BCL6 5´UTR 
(Figure 1C). Compared with MYC SNP variants, MYC mutations were predominated by 
C>T and G>A transitions, thus had a higher transition/transversion ratio than the MYC SNP 
variants (10.1 versus 4.9, Figure 1D).
 Mutations in the MYC Coding Sequence
 Mutation Profile—Among the 750 DLBCL patients, 254 point mutation events 
(Supplementary Table S1) were found in the MYC CDS region harbored by 161 patients 
(21.5% of the DLBCL cohort). However, 39% of these CDS mutations were synonymous 
mutations, and nonsynonymous mutations resulting in mutated Myc proteins (MUT-Myc) 
were found in only 121 patients (16.1% of the DLBCL cohort), 75% of which were 
heterozygous.
Most of these nonsynonymous mutations were missense mutations (Figure 1E). According 
to the in silico functional prediction models, 77% of the missense and nonsense mutations 
had the potential to affect Myc function.
These nonsynonymous mutations were scattered throughout the 439 codons of Myc with 
one to four occurrences of each mutation (Figure 1F). The frequency of hotspot mutations 
within or near MBI, for example T58 mutations found in four DLBCL patients, was much 
lower than that found in Burkitt lymphoma (8,14), and there was another mutation cluster 
near MBII extending to residue 185. F138 mutations were found in four DLBCL patients 
including two patients carried concurrent T58A mutations.
 Impact of Nonsynonymous MYC Mutations and SNPs on Patient Survival—
No clinical parameters significantly differed between the MUT-Myc and WT-Myc groups of 
the training set, except that MUT-Myc patients with germinal center B-cell–like (GCB) 
DLBCL had significantly higher frequency of primary nodal (versus extranodal) origin 
(Table 1). Molecularly, the MUT-Myc group compared with the WT-Myc group had 
significantly higher frequencies of MYC 5´UTR mutations (P < 0.0001), CD10 (P = 0.0052) 
and PI3K expression (P = 0.048), but less frequently nuclear p52 expression (P = 0.0044). 
Moreover, MUT-Myc patients with GCB-DLBCL more frequently had MYC 
rearrangements (36.8% versus 11.7% in the WT-Myc group, P = 0.011) and less frequently 
expressed CD30, whereas MUT-Myc patients with activated B-cell–like (ABC) DLBCL 
more frequently had BCL6 rearrangements (68.8% versus 36.8%, P = 0.015) and p63 
expression (Supplementary Table S2).
Compared with the WT-Myc group, the MUT-Myc group showed trends toward better OS (P 
= 0.08) and PFS (P = 0.05), and patients with nonsynonymous SNPs had significantly better 
OS (P = 0.015, Figure 2A) and PFS (P = 0.01). When analyzed in GCB-DLBCL and ABC-
DLBCL separately, the better survival of MUT-Myc and SNP-Myc groups than the WT-Myc 
group remained significant or with border-line P values, except that MUT-Myc ABC-
DLBCL versus WT-Myc ABC-DLBCL had only slightly better OS [P = 0.43] and PFS [P = 
0.44]) (Supplementary Figure S1A–B). Trends for better survival rates were also associated 
with Myc SNVs (mutations or SNPs) in the validation set (Figure 2B). Between 
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homozygous and heterozygous mutations or SNPs, no significant difference in patient 
survival was observed (Supplementary Figure S1C–D). Patients with the Myc-11S germline 
variant had significantly better survival than those with the canonical WT-Myc-11N in the 
entire (combined training and validation) cohort (Figure 2C). Lists of discovered Myc 
mutations and SNPs and the associated GEP accession codes and clinical outcomes are 
shown in Supplementary Table S3.
However, multivariate survival analysis including clinical parameters and Myc mutation and 
expression status indicated that Myc protein expression levels but not Myc mutation status 
independently predicted poorer OS and PFS, although the presence of Myc mutations 
trended toward conferring better OS (hazard ratio [HR]: 0.61; P = 0.11) and PFS (HR: 0.57; 
P = 0.057) (Supplementary Table S4).
 Prognostic Impact and Heterogeneity of Myc Mutations—Among the R-CHOP-
treated patients for survival analysis (n=602), missense mutations at T58, S62, S67, P79, 
R83, F138, A141, P164, S175 and A185 occurred in at least two patients. We found these 
recurrent Myc mutations (defined as n ≥ 2 occurred at a same AA) were associated with 
differential patient survival independently of Myc expression. Mutations at T58 and F138, 
which have been correlated with increased Myc stability, gain-of-function and reduced 
response to apoptosis in vitro (13,14,18) , had relative high occurrence in our cohort 
compared with other mutations, were all overexpressed, and were associated with 
significantly poor survival (Figure 2C). In contrast, group of other recurrent mutations (S62, 
S67, P79, R83, A141, S175 and A185 mutations) was associated with significantly better 
survival than WT-Myc (Figure 2C). Among these mutations, S62 mutations have been 
associated with impaired transforming ability and normal apoptosis function in vitro and in 
vivo (15,16) . According to the in silico functional prediction models, all the mutations at 
these recurrent spots except those at P79 had functional impact.
Nonsense, frame-shift and splicing mutations leading to a truncated Myc protein or 
substantial amino acid changes were also found associated with significantly better survival 
than WT-Myc (Figure 2C). The rest of MUT-Myc which have not been functionally 
characterized in the literature were still associated with significantly better OS in combined 
training and validation sets (Figure 2D) but not PFS (P = 0.15) compared with the WT-Myc 
cases.
 Prognostic impact of Wild-type and Mutated Myc Overexpression—Myc 
expression levels were significantly lower in the SNP-Myc group compared with the WT-
Myc and MUT-Myc groups (Figure 2E). There was no significant difference in Myc levels 
between the overall MUT-Myc and WT-Myc groups, but we did observe a higher mean level 
of Myc expression in the MUT-Myc GCB-DLBCL group compared with the WT-Myc GCB-
DLBCL group in the training set only (P = 0.047).
High expression level of the canonical Myc (i.e., WT-Myc-11N) correlated with 
significantly poorer patient survival; Figure 2F shows the OS curve in overall DLBCL using 
a 70% cutoff for Mychigh, i.e., ≥70% of tumor cells staining positive on 
immunohistochemistry analysis (30). This adverse prognostic effect was significant in both 
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GCB-DLBCL (P=0.0019) and ABC-DLBCL (P=0.039) (Figures not shown). In contrast, 
high level of the Myc-11S germline variant showed trends toward conferring better survival 
(Figure 2G). Myc overexpression did not have significant prognostic effect in the overall 
MUT-Myc group (for OS, P = 0.22). After the exclusion of patients with T58 and F138 
mutants, which were all expressed at high levels and correlated with significantly poorer 
survival (Figure 2C), patients with high expression levels of non-T58/F138 MUT-Myc did 
not have significantly poorer survival with those with low MUT-Myc expression levels (P = 
0.62 in overall DLBCL, Figure 2H; P = 0.97 in GCB-DLBCL and P = 0.99 in ABC-
DLBCL, Supplementary Figure S1E–F), but significantly better overall survival than 
patients with overexpressed WT-Myc (P = 0.031 in overall DLBCL). Breaking down into 
different types of MUT-Myc in Figures 2C–D, analysis showed similar results: expression 
levels of MUT-Myc with recurrent non-T58/F138 mutations (Figure 2I), nonsense, frame-
shift, or splicing mutations (Figure 2J), or other uncharacterized Myc mutations (Figure 2K) 
did not show prognostic effects. Patients with high expression levels of these Myc mutants 
showed significant or trends for better survival than those with overexpressed WT-Myc 
(Figures 2F, I–L).
 Prognostic Analysis in the Presence or Absence of MYC Rearrangement—
Since approximately 27.3% of the MUT-Myc group had MYC rearrangements (significantly 
higher compared with the 10% of the WT-Myc group, P = 0.00094, Supplementary Table 
S2) which has been shown as a significant adverse prognostic factor, we compared the 
survival outcomes of the WT-Myc and MUT-Myc groups within the MYC rearranged 
(MYC-R+) and MYC non-rearranged (MYC-R−) DLBCL patients separately. In both the 
training and validation sets, the MUT-Myc group showed trends toward better survival 
outcomes compared with the WT-Myc group only in the absence of MYC rearrangements 
(i.e., MUT-Myc/MYC-R− versus WT-Myc/MYC-R− but not MUT-Myc/MYC-R+ versus 
WT-Myc/MYC-R+, Supplementary Figure S1G–J). MYC rearrangements correlated with 
significant poorer prognosis in both WT-Myc and MUT-Myc GCB-DLBCL groups 
(Supplementary Figure S1K–L, MYC-R+ versus MYC-R−). Among the 13 MUT-Myc/
MYC-R+ cases, 4 cases had T58 and/or F138 mutations (totally only five T58/F138-MUT-
Myc cases had MYC rearrangement status available) with significantly poorer survival. 
After excluding these cases from the MUT-Myc/MYC-R+ group, there were still no 
significant difference in survival outcomes between the MUT-Myc/MYC-R+ and WT-Myc/
MYC-R+ groups. Comparison of Myc expression levels between the MUT-Myc, WT-Myc, 
and SNP-Myc groups within the MYC-R− and MYC-R+ subsets are shown in 
Supplementary Figure S2A–C.
 Mutations in the Untranslated Regions
 5´UTR mutations—Compared with the MYC CDS and 3´UTR, the MYC 5´UTR had a 
higher mutation rate in our cohort (Supplementary Table S1), with the mutations distributed 
widely starting from the 9th nucleotide of the first exon (Figure 3A).
MYC-5´UTR mutations harbored by 139 (19.8%) of the DLBCL cohort were associated 
with MYC-CDS mutations, Bcl-6 expression, a lower complete remission rate 
(Supplementary Table S5, Table 1), and differential prognostic impact in the training (no 
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impact) and validation (significantly poorer PFS) cohorts (Figures 3B–C). Multivariate 
survival analysis indicated that MYC-5´UTR mutation was not a significant prognostic 
factor. However, in patients without MYC rearrangements, MYC-5´UTR mutations trended 
toward conferring poorer OS in the training set and poorer PFS in the validation cohort 
(Figures 3D–E).
 3´UTR mutations—Compared with mutations in the MYC CDS and 5´UTR, MYC-3
´UTR mutations (Figure 3F) were less frequent (Supplementary Table S1) occurring in 5.8% 
of DLBCL patients. Half of these mutations occurred in the microRNA targeting sites 
according to TargetScan. However, MYC-3´UTR mutation status did not correlate with Myc 
expression levels (Supplementary Table S5). These mutations, the affected microRNA 
targeting sites, and associated clinical outcomes are listed in Supplementary Table S6.
The MUT-MYC-3´UTR group had a higher proportion of men than the WT-MYC-3´UTR 
group (Table 1). The overall MUT-MYC-3´UTR group did not have significantly poorer 
survival than patients with WT-MYC-3´UTR in the training and validation sets (Figures 3G–
H). However, multivariate survival analysis adjusting clinical parameters indicated that 
MYC-3´UTR mutation was an independent prognostic factor for poorer OS (HR: 2.23; P = 
0.024) but not PFS (HR: 1.85; P = 0.079) (Supplementary Table S4). MYC-3´UTR 
mutations were found recurrently at *2G, *22C, *83G, *345C and *368C which were 
associated with significant poorer survival than WT-MYC-3´UTR (Figures 3I–J), although 
these mutations were not concurrent with MYC rearrangements.
 Gene Expression Profiling Analysis
 Comparisons between WT-Myc and MUT-Myc—By supervised clustering analysis, 
no genes showed significantly differential expression between the MUT-Myc and WT-Myc 
groups (overall cohort or only Mychigh subcohort), or between MUT-MYC-5´/3´UTR and 
WT-MYC-5´/3´UTR groups. Individual analysis of particular mutation types showed 
differential expressed genes involved in proliferation, metabolism and apoptosis 
(Supplementary Figure S2D–G, Supplementary Table S7), but the significance of these 
analyses was hindered by small numbers and the heterogeneity of the MUT-Myc cases likely 
because some patients carried multiple mutations. Notably these signatures included genes 
involved in Ras/Rho GTPase signaling which interacts with the Myc T58 residue (10,13) 
and can cooperate with Myc during tumorigenesis (32).
 Comparisons between WT- or MUT- Mychigh and Myclow—We further identified 
the GEP signatures of Myc overexpression (Mychigh GEP signatures) in the WT-Myc and 
MUT-Myc groups separately, and compared these GEP signatures (Figures 4A–D, Table 2). 
Differentially expressed genes were shown between WT-Mychigh and WT-Myclow in overall 
DLBCL, GCB-DLBCL, and ABC-DLBCL, and between MUT-Mychigh and MUT-Myclow 
in overall DLBCL and GCB-DLBCL but not in ABC-DLBCL even with a high false 
discovery rate (FDR) threshold of 0.50. These GEP signatures include MYC, some genes 
which have important oncogenic roles in transformation by Myc (for example, CDCA7L, 
UVBL2, MKI67IP, NOP16, MINA, and DDX18), and genes which regulate MYC/Myc (for 
example, PRKDC, PURB, SKP2, NME2, CSNK2A2, APEX1, and AIMP2).
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All the WT-Mychigh and MUT-Mychigh GEP signatures are characterized by strong 
proliferation and growth signatures (especially for WT-Mychigh ABC-DLBCL) resembling 
those identified by previous studies (33,34). However, MUT-Mychigh GEP signatures also 
included downregulation of CCND2 (cyclin D2) and JUND in overall DLBCL, and 
downregulation of CCND1 (cyclin D1) and TAF13 RNA polymerase II whereas 
upregulation of COMMD5 (which negatively regulates cell cycle transition and 
proliferation) in GCB-DLBCL. In contrast, in WT-Mychigh GCB-DLBCL (versus WT-
Myclow GCB-DLBCL), CDKN1B (inhibitor of cell cycle progression) and ANKRD12 
(which inhibit transactivation) were downregulated. STAT3 was significantly upregulated in 
WT-Mychigh DLBCL but downregulated in MUT-Mychigh GCB-DLBCL.
Expression of apoptotic genes also showed differences between WT-Mychigh and MUT-
Mychigh GEP signatures. Proapoptotic HRK was significantly upregulated in MUT-Mychigh 
but not in WT-Mychigh DLBCL, which instead had upregulation of PDCD5 (which promotes 
p53-mediated apoptosis) (in DLBCL and GCB-DLBCL), BID, and GNL3 (which stabilize 
MDM2) (in ABC-DLBCL). Other upregulated genes having roles in regulating the p53 
pathway included EEF1E1, HINT1, PRKDC, CHEK1, YWHAG, DNAJA3, HIVEP1, 
PSME3, MTA1, CSNK2A2, AIMP2, USP7, and PHF1 in WT-Mychigh ABC-DLBCL, 
EIF5A in WT-Mychigh GCB-DLBCL, APITD1 in WT-Mychigh DLBCL, and FBXO11 in 
MUT-Mychigh DLBCL. In contrast, In MUT-Mychigh GCB-DLBCL, proapoptotic RASSF4 
and DAPK1 were downregulated compared with MUT-Myclow GCB-DLBCL.
Moreover, in WT-Mychigh ABC-DLBCL (versus WT-Myclow ABC-DLBCL), several T-cell 
marker genes (CD4, GIMAP1, TRA@, and FOXP3) were downregulated but C1QBP 
(which inhibits the complement subcomponent C1) was upregulated. NCR3LG1 (which 
triggers natural killer cell activation) was upregulated in WT-Mychigh (versus WT-Myclow) 
GCB-DLBCL. In MUT-Mychigh GCB-DLBCL, MS4A2 (FCER1B, important for mast cell 
responses) was upregulated whereas IL18BP (which encodes an inhibitor of the 
proinflammatory cytokine IL18) was downregulated. Other potentially important signatures 
included downregulation of IL10RA, TNFRSF25, MIR155HG and ATXN1 whereas 
upregulation of EXOSC2 (components of the RNA exosome complex), HSPD1 and 
SMARCA4 in WT-Mychigh GCB-DLBCL, upregulation of LYN, PIK3R2 and EXOSC8 
whereas downregulation of FYN in WT-Mychigh ABC-DLBCL, and downregulation of 
IL6ST and FYB whereas upregulation of BACH2, MAP3K4, RITA1 and ZBED3 in MUT-
Mychigh GCB-DLBCL. GAS5 and MIR17HG were upregulated in both WT-Mychigh and 
MUT-Mychigh versus Myclow DLBCL.
 Comparisons between WT-Myc and MUT-Myc groups Using Unpaired t Test
—By unpaired t test, the MUT-Myc group compared with the WT-Myc group had 
significantly (P < 0.05) higher levels of MDM2, TP63, CD10/MME and CD22, and 
significantly lower levels of CD44, ICAM1, JAK3, STAT3, STAT5A, TNFSF13B/BAFF, 
CTLA4 and ICOS mRNA, as well as subtle changes in HLA, PMAIP1/NOXA, TP53, 
CDKN2A, BCL2, BCL2L11/BIM (which mediates the proapoptotic function of Myc 
(17,35)), BID, CHUK/IKK1, IKBKB, NFKBIA and NFKBIZ expression, but not in 
MIR17HG (which mediates the oncogenic function of Myc (36)), E2F1 and EZH2 levels 
(Supplementary Figures S3–S4). Genes encoding regulators of Myc degradation/stability 
Xu-Monette et al. Page 9













according to the literature, such as FBXW7, SKP1/2, PIN1, GSK3, PP2A subunits (13), did 
not show significantly differential expression between the MUT-Myc and WT-Myc groups. 
Nonetheless, the MUT-Myc group had significant lower FBXW9 expression compared with 
both WT-Myclow and WT-Mychigh groups.
 Comparison of Protein Expression Levels between WT-Myc and MUT-Myc groups Using 
Unpaired t Test
The MUT-Myc group compared with the WT-Myc group had significantly increased CD10 
and decreased nuclear p52 levels. Expression of p53, Ki-67, pAKT, c-Rel, Bcl-2 and p63 
levels may also be affected by Myc mutation status (Supplementary Figure S5).
 Functional Studies of MYC Mutations and SNPs
We made MYC expression constructs for three mutants (S159R, G160S, and P164L) and 
two germline variants including N11S and P57S (by SNP rs28933407), and introduced them 
into MYC-null Rat1a fibroblasts. We first determined the expression of Myc in Rat1a cells 
and found that all three mutants and the germline variant N11S resulted in lower Myc 
protein levels, whereas P57S variant had higher Myc expression, in line with a previous 
report (P57S was considered as a Myc mutant) (17) (Figure 4E). We seeded 5×104 cells in 6-
well plates and 72 h later, adherent cells were enumerated. Cells with Myc-P57S grew 
fastest and cells with WT-Myc grew modestly faster than did the controls with the parental 
vector (Figure 4F). Cells with Myc-N11S and Myc-P164L proliferated at similar rates as 
WT-Myc, yet cells with Myc-S159R and Myc-G160S had a significantly slower rate than 
WT-Myc. We next asked whether any of the mutations altered the well-known ability of 
Myc overexpression to sensitize cells to apoptosis induced by serum withdrawal. Cells 
expressing WT and N11S Myc were sensitized to serum withdrawal-induced apoptosis, 
while cells with P57S, S159R, G160S and P164L Myc showed apoptosis resistance (Figure 
4G). In anchorage-independent colony formation assay, Myc-P57S greatly enhanced the 
transformation ability compared to WT-Myc, consistent with the previous report (17); 
however, N11S, S159R, G160S and P164L Myc had compromised transformation ability 
compared with WT-Myc (Figure 4H). To further assess the tumorigenesis of these Myc 
mutants in vivo, xenograft in nude mice was applied. Rat1a cells stably expressing WT-Myc 
or its mutants were subcutaneously implanted to 8 weeks old male nude mice (10 
implantation each). Eighteen days post inoculation, significant tumors were visible in mice 
injected with cells expressing P57S, WT, and P164L Myc with different tumor volumes; 
cells with G160S, S159R and N11S were able form tumors at day 27, 27 and 39 respectively 
compared to cells with the parental vector (Figure 4I). Tumorigenesis effect (P57S >WT 
>P164L >G160S >S159R >N11S, Figure 4I) was more correlated with Myc expression 
levels (P57S >WT >P164S >G160S >S159R and N11S, Figure 4E) than colony formation 
(P57S >WT >S159R >G160S >N11S >P164L, Figure 4H), cell proliferation (P57S >WT, 
P164L, and N11S >G160S >S159R, Figure 4F), or apoptosis (WT >N11S >S159R >P164L, 
G160S, and S159R, Figure 4G). Nonetheless, these data suggest that a substantial number of 
MYC CDS mutations are of “loss-of-function” rather than “gain-of-function”.
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In 750 de novo DLBCL patients, we found somatic mutations either in the MYC CDS or 
UTR in 33.3% of DLBCL patients; 71.4% of these mutations were heterozygous. 
Nonsynonymous mutations were found in 16.1% of DLBCL patients. The mutation 
frequency in DLBCL by previous studies was 32% for MYC exon 1 and 2 areas by Sanger 
sequencing, 6.3% for MYC-CDS by next generation sequencing (25,26), and 29% for BCL2 
nonsynonymous mutation by RNA-seq and Sanger sequencing methods (37). We 
acknowledge the limitation of our data lacking paired normal DNA for each patient, and the 
potential false mutations due to sample and sequencing limitations. However, the frequency 
(6.5%) of the Myc-11S germline variant found in our cohort was comparable to the 7.2% 
and 8.1% by two previous studies (38) (38,39). Myc-N11S was associated with better 
survival in our cohort, and was controversially associated with, or not associated with breast 
cancer risk by the two previous studies.
Supplementary Table S8 and Figures 4J–K summarize the major findings by this study. The 
effects of Myc mutations on Myc stability, function, and apoptosis have been inconsistent in 
previous studies (8,13). Contrary to the notion that tumor-derived MYC mutations are 
associated with gain-of-function (10,12) and poorer clinical outcomes, our study showed 
that most Myc mutants (resulted from nonsynonymous MYC-CDS mutations), carried by 
approximately 6% to 15% (i.e., the frequencies for group 2 and 3 mutations in Figure 2C 
and all non-T58/F138 mutants in Figures 2C–D) of DLBCL patients, were often associated 
with better patient survival compared with WT-Myc (NG_007161.1), regardless of Myc 
expression levels. This correlation and functional study results may suggest that many Myc 
mutations attenuated Myc oncogenic function, potentially due to functional changes or 
haploinsufficiency effects (40). Attenuated pro-apoptosis function may paly roles in 
tumorigenesis (17,18,41). Moreover, identified Mychigh GEP signatures may suggest that to 
a certain extent, there were differences in tumor survival, proliferation, and 
microenvironment between the WT-Myc and MUT-Myc groups.
In contrast, T58 mutations, which are frequent in BL and have gain-of-function in vitro and 
in vivo (13), were associated with significantly poorer survival than other DLBCL patients. 
However, the occurrence was low in DLBCL (0.8% of the training set, and 0.5% of the 
combined training and validation cohorts) and associated with MYC rearrangement (an 
independent prognostic factor for adverse survival). In addition, the recurrent MYC-3´UTR 
mutations in 1.3% of DLBCL patients were associated with significant poorer survival than 
WT-MYC-3´UTR. TargetScan indicated that *22C, *83G, *345C of MYC-3´UTR are 
targeted by miR-196b, miR-33b, and miR-429, respectively. Intriguingly, 3´UTR mutations 
were not associated with Myc overexpression, suggesting the presence of MYC suppression 
by multiple microRNAs (42) and posttranslational regulations, and that the molecular 
mechanisms underlying the adverse prognostic impact of these 3´UTR mutations may not be 
simply Myc activation due to the disruption of microRNA-mediated MYC suppression. GEP 
analysis showed that TNRC6B; which plays important roles in microRNA-mediated 
suppression, was significantly downregulated in patients harboring recurrent MYC-3´UTR 
mutations. In addition, MAGEA2/MAGEA2B and ZNF415 which inhibit p53 transcription 
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activities were upregulated, and RAD1 which plays a role in DNA repair was downregulated 
(Supplementary Table S7).
In this study, MYC mutations were not associated with TP53 mutations which increase 
genomic instability. It has been proposed that MYC mutations originated from aberrant 
somatic hypermutation initiated by activation-induced cytidine deaminase (AID) (25). In the 
present study, the following features of MYC mutations resemble those of AID activities, 
which may support this origin hypothesis: (a) the predominance of single nucleotide 
mutations; (b) the elevated transition/transversion mutation ratios compared with SNP 
variants (Figure 1D) (25); (c) the high to low mutation rate ranged from the 5´UTR, CDS, to 
3´UTR, consistent with the AID action pattern (Figure 4J); (d) the association between CDS 
and 5´UTR mutations; (e) the higher frequency of MYC mutations in MYC and BCL6 
rearranged cases (MYC rearrangement is thought to be mediated by AID activities (43)) 
(supplemental Table S2); and (f) the elevated mutation rate in the MYC 5´UTR compared 
with other genes we sequenced concurrently (except BCL6 5´UTR) (Figure 1C) (25,44–46). 
MYC translocation break-points in DLBCL may have affected the mutation rate in 5´UTR 
and CDS (47,48). The predominance of heterozygous instead of homozygous mutations 
suggested that most mutations happen during or after the translocation event. Moreover, the 
association between MUT-5´UTR and Bcl-6 expression, and between MYC-CDS mutation 
and BCL6 rearrangement in ABC-DLBCL (Supplementary Table S2 and Supplementary 
Table S5), as well as the high transition/transversion ratio of MYC mutations may suggest 
that genome instability caused by Bcl-6 expression (49), and loss of protective high-fidelity 
repair (50) may be additional mutation mechanisms during lymphomagenesis. As most 
MYC-CDS and MYC-5´UTR mutations did not appear to adversely impact prognosis, our 
results suggest that most MYC mutations were just passenger mutations acquired during 
tumorigenesis driven by other oncogenic mechanism. This may also explain why the ABC 
subtype (post-GC) having high AID expression (43) also had MYC mutations (with a lower 
frequency than the GCB subtype, Table 1) which did not show significant prognostic effect 
or Mychigh GEP signatures. These MYC mutations might be insufficient for tumor onset, 
and occurred either during GC reaction or concurrently with other post-GC transforming 
events.
In summary, MYC mutations are also present in DLBCL (in addition to Burkitt lymphoma) 
and have differential functional and clinical effects. Particular mutations such as T58/F138 
mutations and some MYC-3´UTR mutations, were found in approximately 2% of DLBCL 
cases and associated with significantly poorer prognosis. In contrast with these infrequent 
mutations which may have roles in lymphomagenesis, most MYC-CDS mutations (in 
approximately 15% of DLBCL) were associated with better clinical outcomes compared 
with the canonical WT-Myc-11N and probably passenger mutations during 
lymphomagenesis. The Myc-N11S germline variant (in 6.5% of DLBCL) was also 
associated with better clinical outcomes compared with the canonical WT-Myc-11N. This 
study provides knowledge of MYC mutations and variations in DLBCL, supports the 
oncogenic role of the canonical WT-Myc, and has important clinical and therapeutic 
implications.
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MYC mutations in diffuse large B-cell lymphoma (DLBCL) are not as well studied as 
MYC translocations, another form of MYC genetic aberrations. This study fills in this 
knowledge gap by profiling MYC gene mutations and germline variations in a large 
group of DLBCL patients, and attempted to understand their impact on Myc function and 
clinical outcomes. We found a wide range of single nucleotide variations of MYC genes 
in DLBCL which correlated with different clinical outcomes. Mutations known to have 
gain-of-functions implicated in the pathogenesis of Burkitt lymphoma by previous 
studies were not frequent in DLBCL, whereas most MYC mutations were associated with 
better clinical outcomes. These results suggested that most MYC mutations in DLBCL 
were probably passenger mutations instead of driver mutations during lymphomagenesis. 
This study showed, for the first time, the clinical significance of MYC mutations in 
DLBCL, and supports the oncogenic role of MYC.
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Schematic illustration of the structure of MYC gene and Myc protein, and the composition 
and occurrence of MYC mutations. (A) Three MYC exons (top) are transcribed into an 
mRNA (middle) with untranslated regions (UTR) and the coding sequence (CDS), and then 
translated into the Myc protein with MYC box I (MBI, 44–63 aa) and MYC box II (MBII, 
128–143 aa) in the N-terminal domain (NTD), MYC box III (MBIII including A and B), 
nuclear localization sequence (NLS), and the basic helix-loop-helix leucine zipper motif (B-
HLH-LZ, 355–439 aa, involved in the dimerization with MAX and interacting with other 
HLH proteins) motif in the C-terminal domain (CTD). TAD indicates transactivation 
domain. (B) Occurrence of the SNPs (indicated in parentheses) in the 5´UTR, CDS and 3
´UTR found in the DLBCL cohort. The SNP nucleotide positions are according to the 
translation start site resulting in the canonical Myc protein (439 aa). (C) Comparison of the 
mutation rate of 10 genes we sequenced for the DLBCL cohort. (D) Patterns of the MYC 
variations (SNPs and somatic mutations) found in the DLBCL cohort. (E) Proportions of 
silent, missense, nonsense, frame-shift, and splicing mutations in the MYC CDS found in 
the DLBCL cohort. (F) Frequencies of missense and nonsense Myc mutations. Numbers in 
parentheses indicate occurrence in the DLBCL cohort.
Xu-Monette et al. Page 18














Impact of nonsynonymous Myc variants on patient survival. (A–B) Overall survival of 
patient groups with wild-type (WT), mutated (MUT) or polymorphic (SNP) Myc in the 
training and validation sets. (C–D) Different types of Myc variants were associated with 
differential prognosis. (E) Comparison of Myc expression levels between groups with WT-, 
MUT- or SNP-Myc. (F) Overexpression of WT-Myc-11N correlated with significantly 
poorer survival. (G–H) Expression of the Myc-11S variant and non-T58/F138 MUT-Myc 
did not impact survival significantly. (I–K) Expression of different types of MUT-Myc 
(group of recurrent non-T58/F138 mutants; frame-shift or nonsense mutants; and other 
MUT-Myc) did not impact survival significantly. (L) After exclusion of Myc mutants in 
Figures I–J, the MUT-Mychigh group continued to show better survival compared with the 
group with overexpressed WT-Myc-11N with a marginal P value.
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Mutations in the MYC untranslated regions (UTR). (A) Distribution of mutations in the 
MYC 5´UTR. The nucleotide positions shown before the parentheses are in relation to the 
translation start site for canonical Myc protein (439aa). Numbers in parentheses indicate 
occurrence frequency in our cohort. (B–C) MYC 5´UTR mutations did not correlate with 
survival in the training set, but did correlate with significantly poorer PFS in the validation 
set. (D–E) In patients without MYC rearrangements, MYC 5´UTR mutations trended toward 
conferring poorer OS in the training set and poorer PFS in the validation sets. (F) 
Distribution of mutations in the MYC 3´UTR. Numbers in parentheses indicate occurrence. 
Mutations disrupting the known microRNA targeting sites (according to TargetScan) are 
highlighted in red. (G–H) The overall MUT-MYC-3´UTR group did not show significant 
poorer survival in the training and validation sets. (I–J) 3´UTR mutations recurrently (n ≥ 2) 
occurred at *2G, *22C, *83G, *345C, and *368C were associated with significantly poorer 
survival.
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Gene expression profiling (GEP) analysis, and functional studies of Myc variants in Rat1a 
cells. (A) GEP signatures for high levels (≥ 70%) of Myc expression (Mychigh) in WT-Myc 
patients with germinal center B-cell–like (GCB) DLBCL (false discovery rate [FDR] < 
0.20). (B) GEP signatures for Mychigh in WT-Myc patients with activated B-cell–like (ABC) 
DLBCL (FDR < 0.05) with a cutoff of 1.65 for fold change of differential expression. (C) 
GEP signatures for Mychigh in MUT-Myc GCB-DLBCL patients (FDR < 0.20). (D) GEP 
signatures for Mychigh in overall MUT-Myc patients (FDR < 0.01). (E) Western blot analysis 
of expression of wild-type Myc and Myc variants in Rat1a cells transduced with retroviral 
vector expressing wild type Myc and Myc variants. (F) Cell proliferation analysis of wild-
type Myc and Myc variants. Cells with the parental vector were used as control. Error bars 
show SEM. (G) Cell apoptosis analysis of wild type Myc and Myc variants using serum 
withdrawal. (H) An anchorage-independent colon formation assay of wild-type Myc and 
Myc variants. (I) Tumorigenecity of cells expressing wild type Myc or its mutants. Note: 
Statistical analysis was performed using one-way ANOVA in (G) to (J) with * indicating 
significant difference (P ≤ 0.05) between wild type Myc and a Myc variant, or two-away 
ANOVA in (K) with α-φ indicating significant difference (P ≤ 0.05) between the marked two 
groups. (J) Schematic illustration for the possible mechanism of MYC mutation and 
rearrangement origin, i.e., the activities of activation-induced cytidine deaminase (AID), 
Xu-Monette et al. Page 21













which depend on MYC transcription activation and can affect up to ∼2kb downstream DNA 
from the transcription initiation site. Abbreviations: SHM, somatic hypermutation; UTR, 
untranslated region; P0, P1, P2, and P3 indicate multiple promoters of the MYC gene. (K) A 
hypothetical model for origin of MYC genetic lesions and effects on Myc expression, Myc 
function and clinical outcomes.
Xu-Monette et al. Page 22
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